MTOR and myeloid sarcoma: We observed an appreciable reduction in phospho-mTOR (S2448) and phospho-s6 (S240/244) in the CRS and MS + CRS groups compared with the control group [phospho-mTOR/t-mTOR: F(2, 9) = 16.528, P < 0.05, P < 0.001; phospho-s6/t-s6: F(2, 9) = 17.193, P < 0.05, P < 0.001], but the total mTOR and s6 levels remained unaltered.